Trial · NCT05564169
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Absolute change from baseline in iADRS score at week 24 | 24 weeks | The iADRS is a linear combination of its two components: the ADAS-Cog11 and the ADCS-iADL. The iADRS is calculated as follows: iADRS = ADCS-iADL + (70 - ADAS-Cog11). Lower scores on the iADRS indicate greater impairment; iADRS scores range from 0 to 129. |
| Secondary | Absolute change from baseline in Mini-Mental State Examination (MMSE) at week 24 | 24 weeks | Mini-Mental State Examination (MMSE) (scores from 0 to 30, with lower scores indicating poorer cognitive performance) |
| Secondary | Absolute change from baseline in ADAS-Cog11 score at week 24 | 24 weeks | The global score, which is the sum of the 11 items, ranges from 0 to 70, with higher scores indicating greater cognitive impairment. |
| Secondary | Absolute change from baseline in ADCS-ADL score | 48 weeks | Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory scale (ADCS-ADL) (scores from 0 to 78, with lower scores indicating worse function) |
| Secondary | Clinical Responder rate | 24 weeks | Clinical response defined as decrease from baseline at week 24 in ADAS-cog of ≥4, without deterioration in ADCS-ADL (ADCS-ADL change ≥ 0 between baseline and timepoint) or worsening in the CIBIC-plus scale (response CIBIC in 1-3\] or no change \[CIBIC in 4\]). |
| Secondary | CIBIC-plus | 24 weeks | Clinician's Interview-Based Impression of Change plus Caregiver Input (CIBIC-plus), a seven-point categorical rating scale ranging from 1 (marked improved) to 7 (markedly worse) compared with baseline. |
| Secondary | Absolute change from baseline in CDR | 24 weeks | Clinical Dementia Rating (CDR), scores from 0 to 18, with higher scores indicating worse dementia |
| Secondary | Time to severe dementia (MMSE<10) | 24 weeks | Mini-Mental State Examination (MMSE) (scores from 0 to 30, with lower scores indicating poorer cognitive performance) |
| Secondary | Absolute change from baseline in ADAS-Cog11 score at week 48 | 48 weeks | The global score, which is the sum of the 11 items, ranges from 0 to 70, with higher scores indicating greater cognitive impairment. |
| Secondary | Absolute change from baseline in ADCS-ADL score at week 24 | 24 weeks | Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory scale (ADCS-ADL) (scores from 0 to 78, with lower scores indicating worse function) |
| Secondary | Absolute change from baseline in Neuropsychiatric Inventory (NPI) at week 24 | 24 weeks | Total NPI-12 score ranges from 0 to 144 (higher = more severe symptoms) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05564169/registered